The Laboratory Manager will be responsible for organizing, implementing and performing laboratory operations. Duties shall include:

• Establishing schedules and work assignments.
• Responsible for management and development of up to 3 employees.
• Periodic review and implementation of SOPs
• Drafting and implementing new SOPs as needed
• Initiate training and development of staff
• Oversee inventory management and supplies procurement
• Clinical grade sample processing, quality control
• Ensure compliance with corporate policies, standard operating procedures, local and other applicable regulatory requirements and best practice guidelines.
• Establish and maintain effective relationship with Regenexx medical and clinical support staff.
• Provide technical feedback to ensure that clinical activities are in line with overall goals.

Preferred Skills:

• Superior written and verbal communication skills are essential.
• Regulatory knowledge of good medical science practices, and human cell therapies preferred.
• Proficient in Microsoft Access, Word, Excel a plus.
• Effective critical thinking and problem solving.
• Ability to handle and prioritize multiple assignments in a fast-paced work environment.
• Ability to coordinate and lead multiple projects simultaneously.
• Ability to identify issues proactively, find a resolution and follow through to completion.
• Ability to be self-directed and take initiative.
• Must be able to work effectively as part of a multi-disciplinary team

Education and Experience:

Experience with cell culture techniques is essential.  Bachelors in Life Sciences, Immunology, Medical Engineering, Medical Technology or related discipline plus a minimum of 7 years relevant experience, or a  Master’s degree with a demonstrated background.  Must be willing to work evenings, weekends, and holidays.   Stematix Cayman offers a competitive salary, retirement investment, and health insurance.We appreciate all applicants, only those to be interviewed will be contacted.

To contact us, please send us an email at info@stematix.com

Our our new Cayman Islands site, Regenexx(tm) Cayman, was opened in September with our partners Regenerative Sciences LLC of Colorado (RSI).

We’re proud to announce that the site has treated more than a dozen patients through the end of October, and the numbers are increasing.

The laboratory is a state-of-the-art facility designed and implemented by a joint of Stematix-RSI team.  Regenexx Cayman also treated its first NFL player. Patient results are consistent with those of more than 1100 patients previously treated in the U.S. at the Centeno-Schultz Clinic (www.regenexx.com).

We hope to continue to treat increasing numbers of patients by offering more advanced orthopedic stem cell procedures than can be found in the U.S. For example, the Regenexx Cayman site can culture cells to greater numbers, differentiate those cells along a certain lineage (like cartilage), and freeze extra cells for future use.

Patients now have a location that’s an easy flight from many American cities without the hassle of traveling to Europe or Asia. In addition, there is no other orthopedic stem cell procedure that has as much published scientific data in terms of patient numbers as Regenexx-C.

Stematix’s Argentina affiliate, Stematix SA (info@stematix.com; +54-11-4001-3116), working through its affiliated physicians, have been treating patients in Buenos Aires using Regenexx procedures since January, 2011.

As always, it is Stematix(tm) policy to offer only treatments which have appropriate regulatory approval, conform to practice of medicine guidelines where they are offered, and conform to International Cellular Medicine Society adult stem cell guidelines.

Dr. Francesca Vitelli, Senior Vice President of Stematix and Board member of the International Cellular Medicine Society attends Vatican Stem Cell Conference.

Representatives from the stem cell business community, such as Stematix, and ministers of health from around the world, along Church leaders, policymakers, ethicists, attended the conference on adult stem cell research, all of them invited by The Pontifical Council for Culture.

The invitation reflects the new strategy of the Catholic Church to end research on embryonic stem cells. The Vatican is spending millions of dollars to support research into adult stem cell therapies.

Read more about this unique scientific and cultural event: VATICAN 9-11 Nov 2011 Catholic Church hosts conference on adult stem-cell research

We would like to announce that on October 20th, Stematix graduated as a Client Company of the Houston Technology Center, HTC.

Opening speeches to the exclusive reception were given by Ernie Cockrell, Jr. (President of the Cockrell Foundation) and Jim McIngvale (”Mattress Mack” of Gallery Furniture), two leading local businessmen who have changed the face of the city of Houston.

Being an HTC Client Company opens doors to networking with local entrepreneurs, corporations and institutions in Texas and Mexico to find potential clients or strategic partners, assistance with business development needs, and opportunities for showcasing the company’s business model and results to VCs and clients alike, enabling the growth of the company.

Certain business milestones reached, including cash flow and a strong scalable business model, trigger graduation from HTC.

Stematix has been a client for three years. In the past year, Stematix has seen considerable expansion, including growth of the Argentina operations and treatments, and launch of Stematix Cayman Ltd, led by our exceptional international teams in Houston, Buenos Aires, and Grand Cayman.

Congratulations to all of you who have contributed so significantly in the achievement of this milestone!

Stematix, Inc. is announcing an initiative to promote regenerative medicine treatments in the field of sports medicine. This initiative will seek to commercialize approved Adult-Stem Cell based therapies for orthopedic treatments.

Most competitive athletes, over the course of a long career, experience various types of severe joint, tendon, ligament, or bone pain due to injury and other factors. In many cases, surgery and extensive rehabilitation are the only alternatives. This leads to long periods of recovery, and can incur huge financial costs. However, new breakthroughs in the field of Regenerative Medicine, most notably Adult-Stem Cell treatments, are now offering a viable alternative to athletes. Treatments using a patient’s own bone-marrow derived stem cells can rapidly speed up the recovery process, and in some cases eliminate the need for surgery altogether.

Stematix, Inc. will be working with various sports teams and insurance carriers to cover the costs of providing approved adult-stem cell therapies to athletes, which will enable them to return to the sports field faster, and will also reduce the long-term costs of providers.

The AmnioCare patch has been developed as an in vivo wound covering to provide a physical barrier to protect tendons and nerves at the surgical site. It is sterile, easy to use, and available for a broad range of clinical indications.

AmnioGenesis is a liquid wound covering product for use in vivo where the AmnioCare patch is either inconvenient of inadequate. AmnioGenesis can be applied directly to the surgical site or mixed with the patient’s own blood to provide an easy to use wound covering offering the unique biologic structure of amniotic tissue.

All tissues are derived from live, healthy donors and are pre-screened during pregnancy according to strict donor selection criteria. From recovery of the tissue at childbirth to timely processing and cryopreservation, all protocols and procedures have been developed to meet or exceed all applicable industry standards for the use of human tissue products.

Part of the Patient Protection and Affordable care Act, QTDP awards were granted to projects showing potential to result in new therapies to treat areas of unmet medical need or to prevent, detect or treat chronic or acute diseases and conditions; to reduce long-term health care costs in the United States; and/or to significantly advance the goal of curing cancer within the next 30 years.

Stematix’s application was reviewed by the QTDP in consultation with the Department of Health and Human Services. Stematix was granted $244, 479.25, the maximum per project amount awarded, to reimburse a portion of research and development investments for its AlloStrome™ cell project.

We recently posted on this blog that Stematix has received approval to initiate a Clinical Trial using our proprietary Allostrome™ cells to improve patient outcomes after acute myocardial infarction. The QTDP award further validates the importance of this project.

Each year cardiovascular disease causes more deaths than cancer in the US, and globally claims 17.1M lives annually. In 2006, a total of 81M Americans were affected by one form or another of cardiovascular disease, with 8.5M suffering from acute Myocardial Infarction (MI), representing in 2009 a cost of $165B direct and indirect costs to healthcare. Today more than ever before, patients can survive a heart attack, yet go on to develop heart failure, resulting in a higher probability of cardiac-related morbidity and mortality.

From:

http://www.nature.com/nm/journal/v16/n7/abs/nm.2170.html

Regenevita LLC plans to initially establish two cellular banking operations: one in McAllen, Texas and the other in Reynosa, Mexico. The Reynosa bank will be located in the newest maternity hospital in Reynosa (opened in 2008) under a 50/50 joint venture with the Secretaria de Salud (Ministry of Health) of the Mexican State of Tamaulipas. The Regenevita facilities will initially bank umbilical cord blood from patient donations and for private families, and Regenevita plans to add capabilities and services to support regenerative medicine delivery in future years.

Emerging Healthcare Solutions focuses on the development of profitable emerging
medical technology, a sector that also includes Amgen (NASDAQ: AMGN), Dendreon Corporation (NASDAQ: DNDN), Smith & Nephew Plc (NYSE: SNN) and Pharmaceutical Product Development (NASDAQ: PPDI).

About Emerging Healthcare Solutions, Inc.

Emerging Healthcare Solutions, Inc. is a medical technology company that works to bring new and innovative medical technologies to the market. The Company’s model is to engage a technology prior to its inflection point in order to maximize the profits available to EHSI as that new technology is adopted. Our common stock is traded under the symbol EHSI.

For more information, visit www.emerginghealthcaresolutionsinc.com or www.regenevita.com